Table 1.
General overview of CyD/drug ICs embedded polymeric electrospun nanofibers used in drug delivery.
| CyD Type | Polymer Additive | Active Molecule | Release Data | Ref |
|---|---|---|---|---|
| β-CyD | PCL | Naproxen (NAP) | Higher NAP release with CyD | [88] |
| β-CyD, HP-β-CyD | Pellethane (TPU) | Naproxen (NAP) | 10 h (NAP-TPU), 32 h (NAP/β-CyD/TPU), 120 h (NAP, HP-β-CyD/TPU) | [91] |
| HP-β-CyD | Hydroxypropyl cellulose (HPC) | Sulfisoxazole (SFS) | 720 min (PCL-PCL-HPC/SFS/HP-β-CyD-IC-NF), >720 min (HPC/SFS/HP-β-CyD-IC-NF) | [92] |
| HP-β-CyD | PVP, PVA, Thiolated chitosan (CS-SH) | Clotrimazole (CZ) | For all nanofibers 80% in 480 min | [94] |
| HP-β-CyD | PVA | Voriconazole (VRC) | 8 h for 100% release | [95] |
| β-CyD, HP-β-CyD | PVP | Meloxicam (MX) | For all nanofibers, 20 min for 100% release | [97] |
| HP-β-CyD | PVP | Meloxicam (MX) | Rapid release (<10 min) | [99] |
| β-CyD | PCL | Tetracycline (TCN) | Drug release occurred up to 2 weeks | [100] |
| HP-β-CyD | Silk fibroin (SF) | Tamoxifen (TAM) | 10% in 22 days in PBS, 50–60% in PBS-EtOH (30%) in 22 days) | [107] |
| β-CyD | PCL | Silver sulfadiazine (SAg) | 80% release from PCL/SAg, 66% release from PCL/SAg/β-CyD | [110] |
| HP-β-CyD | PLLA | Curcumin (CUR) | Higher release at pH of 1. CyD increased drug release. | [112] |
| β-CyD | PVA | Curcumin (CUR) | Higher drug content increased the release rate. | [113] |
| β-CyD | Poly (l-lactic acid-co-ε-caprolactone) (PLACL) | Curcumin (CUR) | 1% CUR interacting with MgO nanoparticles showed higher inhibition of breast cancer cells. | [114] |
| HP-β-CyD | Poly(dl-lactic acid)–poly(ethylene glycol) (PELA) | Hydroxycamptothecin (HCPT) | Higher CyD content increased release rate. The release was slow and took many weeks. | [115] |
| α-CyD and β-CyD |
PCL | Ciprofloxacin | Higher release with initial higher drug loading | [116] |
| SBE-β-CyD | PEO | Aripiprazole (ARP) | Rapid release in 2 min | [119] |
| HP-β-CyD | Cellulose acetate | Asiaticoside (AC) | Higher release with CyD and initial burst release within 300 min | [120] |
| β-CyD | PVA | Allyl isothiocyanate (AITC) | Higher release at 75 °C and followed by 50 and 30 °C. | [121] |
| β-CyD | PEO | Allyl isothiocyanate (AITC) | Higher release with increasing relative humidity | [122] |
| HP-β-CyD | Poly(ethylene glycol)-polylactide (PELA) | Combretastatin A-4 (CA4) and hydroxycamptothecin (HCPT) | Sustained release of CA4 over 30 days, fibers showed significant antitumor efficacy and tumor vasculature destruction | [123] |
| HP-β-CyD | PVP | Flubendazole | The release of a dose of 40 mg in 15 min | [124] |
| M-β-CyD | PLLA | Doxorubicin (DOX) | 17% Decrease in the burst release was observed and followed by a quantifiable sustained release up to 2 days. | [125] |
| HP-β-CyD | PVA | Metoclopramide hydrochloride (MH) | Burst release: 90% release in 2 min | [126] |
| β-CyD derivative | Chitosan | β-Lactamase BlaP protein | CyD increased the stability of the embedded protein | [127] |
| HP-β-CyD | PVP | Plai oil | The release rate ranged was in the order of 10% > 20%~30% plai oil within 24 h. | [131] |
| HP-β-CyD | PVP | Herbal oil | Very rapid release: 50% release in 1 min | [132] |
| β-CyD | PEO | Cinnamon (CEO) | Controlled release in nanofibers via bacterial protease. | [133] |
| β-CyD | PVA | Cinnamon (CEO) | Nanofibers showed excellent antimicrobial activity against E. coli and S. aureus. | [134] |
| β-CyD | PLA | Cinnamon (CEO) | High antimicrobial activity due to released CEO | [135] |
| β-CyD | PVA | Cinnamon (CEO) | Stronger antimicrobial activity with incorporated lysozyme | [136] |
| β-CyD | Chitosan and PVA | Oregano and cinnamon EOs | Lower release of Oregano EO than CEO | [137] |
| β-CyD | PLA | Cinnamaldehyde (CA) | Higher release with increasing CA content | [138] |
| β-CyD | Zein | Eucalyptus EO | Higher antimicrobial activity with increasing EEO content | [140] |
| HP-β-CyD | PLA | Gallic acid | Increasing release rate with CyD incorporation | [141] |
| β-CyD | Pullulan | Perillaldehyde | Higher release with increasing humidity | [142] |
| α-CyD | Xanthan | Hexanal | CyD increased the release rate | [147] |
| γ-CyD | PLA | α-Tocopherol (α-TC) | CyD increased higher release of α-TC. | [148] |
| β-CyD | PAA | Quercetin | Nanofibers showed enhanced release rate than the films | [149] |
| β-CyD | PVA | Retinyl acetate (RA) | Slower release with CyD incorporation | [150] |